Utility of Assessing Early Tumor Shrinkage as an Efficacy Predictor in Patients with Non-Surgically Indicated or Recurrent Esophageal Cancer Treated with Nivolumab plus Ipilimumab
ETS-high, DpR-high, and irAEs might be associated with favorable responses to nivolumab plus ipilimumab. As a predictor of efficacy at an early phase, ETS >0% could be a deciding factor for continuing ICI doublet therapy.
Authors
- Mami Yoshii
- Hiroaki Kasashima
- Kiyoshi Maeda (ORCID: https://orcid.org/0000-0002-5138-4767)
- Takahiro Toyokawa
- Yuichiro Miki (ORCID: https://orcid.org/0000-0003-0116-0922)
- Seiji Natsuki (ORCID: https://orcid.org/0000-0002-9714-5489)
- Masatsune Shibutani (ORCID: https://orcid.org/0000-0002-2164-7394)
- Shigeru Lee
- Hiroaki Tanaka (ORCID: https://orcid.org/0000-0002-2324-0248)
- Tatsunari Fukuoka
- Tatsuro Tamura
Institutions
- Osaka City University (JP)
- Fuchu Hospital (JP)
Publication Details
- Journal
- Oncology
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1159/000540851
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00